FDA advisors voted unanimously on Friday to recommend approval of Moderna’s mRNA-1010 seasonal flu vaccine, branded mFlusiva. Large Phase 3 trials showed 27 percent greater effectiveness than standard shots in adults over 50 and stronger immune responses than high-dose vaccines in those over 65, with a generally favorable safety profile. Earlier attempts by Trump appointees to block review were noted in reporting.